Genmab Announces Leadership Transition as Chief Legal Officer Birgitte Stephensen Retires, Greg Mueller Appointed Successor
Genmab A/S (Nasdaq: GMAB), a leading international biotechnology company focused on antibody-based therapeutics for cancer and other serious diseases, today announced a major leadership transition within its executive team. After more than two decades of distinguished service, Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will officially retire from the company. In her place, Greg Mueller has been appointed as Executive Vice President, General Counsel, and Chief Legal Officer, effective July 1, 2025.
Greg Mueller will report directly to Dr. Jan van de Winkel, Genmab’s President and Chief Executive Officer. He will also join the company’s Executive Committee, which comprises a diverse group of leaders responsible for steering Genmab’s corporate, scientific, commercial, and operational strategies. This committee includes:
- Dr. Tahi Ahmadi, Chief Medical Officer
- Brad Bailey, Chief Commercial Officer
- Chris Cozic, Chief People Officer
- Dr. Judith Klimovsky, Chief Development Officer
- Anthony Pagano, Chief Financial Officer
- Dr. Martine van Vugt, Chief Strategy Officer
- Rayne Waller, Chief TechOps Officer
With his appointment, Greg will be based out of Genmab’s global headquarters in Copenhagen, Denmark.
A Legacy of Legal and Strategic Excellence: Farewell to Birgitte Stephensen
Birgitte Stephensen joined Genmab in 2002, just three years after the company was founded. Over her impressive 23-year tenure, she played a pivotal role in shaping Genmab’s legal infrastructure during a period of remarkable growth and transformation. Her leadership and legal expertise contributed significantly to the company’s successful partnerships, regulatory milestones, and corporate governance.
Commenting on Birgitte’s retirement, CEO Jan van de Winkel, Ph.D., expressed heartfelt appreciation for her invaluable contributions:
“I am deeply grateful to Birgitte for her outstanding service and unwavering dedication during her long career with Genmab. Her impact has been profound—not just in legal affairs but across the entire organization. She has played integral roles in many of Genmab’s most important milestones and has helped to instill a culture of excellence and integrity that will endure long after her departure.”
Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market. She also oversaw the development of the company’s internal compliance programs and intellectual property portfolio, positioning Genmab as a global leader in the antibody therapeutic space.
Welcoming Greg Mueller: A Veteran Legal Executive Joins Genmab
Greg Mueller brings to Genmab more than two decades of global legal experience, most recently from AstraZeneca (AZ), one of the world’s top pharmaceutical companies. Over the past 20 years, Greg held several key legal leadership roles at AZ, contributing to the company’s growth in North America, Europe, and Asia. Notably, for the past 12 years, he served as a member of AZ’s Legal Senior Management Team, holding the roles of:
- Deputy General Counsel, International
- Deputy General Counsel, Corporate
Prior to his corporate career at AstraZeneca, Greg practiced as a corporate transactions attorney at a prominent Canadian law firm. His academic background includes a Bachelor of Commerce (specialist degree) from the University of Toronto and a Law Degree (LLB) from Queen’s University, equipping him with a strong foundation in both business and law.
CEO Jan van de Winkel welcomed Greg’s arrival at a pivotal time for Genmab, as the company deepens its transition into a fully integrated biotech with a growing commercial footprint and expanding research pipeline:
“I am excited to welcome Greg Mueller to Genmab. His extensive experience across legal, compliance, and risk management in a global pharmaceutical environment will be instrumental as we continue our evolution into a fully integrated biopharmaceutical company. As we strive to develop and deliver innovative antibody-based medicines to patients worldwide, Greg’s leadership will be vital in guiding our legal strategy and supporting our long-term goals.”
In his new role, Greg will oversee Genmab’s global legal affairs, including intellectual property rights, corporate governance, compliance and risk management, and serve as the company’s corporate secretary.
A New Chapter for Genmab
This leadership transition reflects Genmab’s ongoing commitment to strong governance, strategic growth, and operational excellence as it continues to expand its pipeline and global presence. With a renewed legal leadership structure, the company is well-positioned to navigate the complexities of the global biotech environment and accelerate its mission to transform the treatment of cancer and other serious diseases through cutting-edge antibody technology.
As Genmab bids farewell to a trusted and long-serving legal leader and welcomes a seasoned industry executive, the company moves into its next phase with renewed momentum and a clear focus on the future.
